Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants’ Efficacy and Harm

This paper by Michael Hengartner has been published in the journal Frontiers in Psychiatry. The abstract says: “Background In current psychiatric practice, antidepressants are widely and with ever-increasing frequency prescribed to patients. However, several scientific biases obfuscate estimates of antidepressants’ efficacy…
Read more

Celexa, Lexapro & the Death of Evidence-Based Medicine

This article has been published on the website of American legal firm Baum Hedlund Aristei & Goldman. It begins: “‘Oh, what a tangled web we weave. When first we practise to deceive!” From Walter Scott’s epic poem, Marmion. This is the story of…
Read more

The hidden epidemic of sexual dysfunction which experts blame on SSRI antidepressants

Jo Macfarlane reports for the Mail on Sunday: SSRI antidepressants could cause ‘life-changing’ sexual problems experts say1 in 8 people were prescribed antidepressants in the past year according to statsBut they can cause serious side effects like libido drop and numb groin…
Read more

Antidepressants Work Better Than Sugar Pills Only 15 Percent of the Time

This article by Adam Piore has been published in Newsweek magazine. It begins: “Five years ago Mark Horowitz seemed an unlikely skeptic of psycho-pharmaceuticals. He had been taking the popular antidepressant Lexapro virtually every day for 15 years. He was so…
Read more

Personal Perspective on the Systematic Review of Serotonin Imbalance Hypothesis for depression and Mechanism of Action for Antidepressants

This interview with Dr. Mark Horowitz is conducted by Fauzia Khan and has been published in The Physician. The abstract says: “Fauzia Khan meets Dr Mark Horowitz, Trainee Psychiatrist and Clinical Research Fellow in the NHS. Mark talks about his journey…
Read more

Ethical issues in psychopharmacology

This paper by L. McHenry has been published in the Journal of Medical Ethics. The abstract says: “The marketing of selective serotonin reuptake inhibitors in the psychopharmacological industry presents a serious moral problem for the corporate model of medicine. In this…
Read more

Follow

Get the latest posts delivered to your mailbox:

Your email address will not be passed to any other organisation. It will only be used to send you new posts made on this website.

MENU